Virta Health shows nutrition therapy may extend life in advanced pancreatic cancer

The trial enrolled patients with stage IV pancreatic cancer, where median life expectancy is just 6 to 12 months

Meiji Seika Pharma launches first-in-human trial of Novel PD-1 agonist for autoimmune diseases

The early-stage study will test the drug’s safety, tolerability and biological effects in humans

Citius Oncology reports promising early trial results for therapy for gynecologic cancers

The Phase 1 dose-escalation trial enrolled 25 evaluable patients and was designed to determine the recommended dose of LYMPHIR

Hopewell Therapeutics sublicenses breakthrough LNP technology to Foxcroft for cancer vaccine development

The two companies will collaborate to evaluate Hopewell’s ttLNPs for clinical applications

FDA grants priority review to Enhertu for high-risk HER2-positive breast cancer

Enhertu recently received Breakthrough Therapy Designation, accelerating development and review for this critical patient population

Starton Therapeutics doses first patient in Phase 2a trial of STAR-LLD for multiple myeloma

The Phase 2 trial, conducted through Starton’s Sargon Site Network, is expanding from two to six sites across the U.S.

ImmunityBio partners with Middle East giants to launch ANKTIVA for cancer patients

To support this launch, ImmunityBio has established a wholly owned subsidiary in Saudi Arabia

Vivere Oncotherapies secures more than $10M to tackle hard-to-treat ‘cold’ tumors

Dr Reddy's inks $370 million licensing deal to sell Immutep's cancer drug Eftilagimod Alfa

Dr Reddy’s will pay Immutep US$ 20 million upfront and could deliver as much as US$ 349.5 million in regulatory and commercial milestones

Kelun-Biotech’s Sac-TMT shows breakthrough results in first-line lung cancer trial

Sac-TMT is a novel human TROP2 ADC with proprietary intellectual property, targeting advanced solid tumors